グラム陰性病原体による院内肺炎の治療におけるセフィデロコル（S-649266）の臨床試験

基本情報

NCT ID: NCT03032380
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 300
治験依頼者名: Shionogi Inc.

概要

The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or healthcare-associated bacterial pneumonia (HCABP) caused by Gram-negative pathogens.

対象疾患

Healthcare-associated Pneumonia (HCAP)Hospital Acquired Pneumonia (HAP)Ventilator Associated Pneumonia (VAP)

介入

Cefiderocol(DRUG)

Meropenem(DRUG)

Linezolid(DRUG)

依頼者（Sponsor）

塩野義製薬株式会社(INDUSTRY)